General Information
Drug ID
DR00124
Drug Name
Fluvastatin
Synonyms
(+)-(3R,5S)-fluvastatin; (-)-(3S,5R)-fluvastatin; (3R,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid; (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3S,5R,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E,3S,5R)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (Z,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoate; 7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; Canef; Canef(TN); Cranoc; Fluindostatin; Fluvas; Fluvas (TN); Fluvastatin & Primycin; Fluvastatin (INN); Fluvastatin [INN:BAN]; Fluvastatina; Fluvastatina [INN-Spanish]; Fluvastatine; Fluvastatine [INN-French]; Fluvastatinum; Fluvastatinum [INN-Latin]; Lescol; Lescol (TN); Lescol XL; Vastin (TN); XU 62320; XU-62320
Drug Type
Small molecular drug
Indication Hypercholesterolemia [ICD11: 5C80.0] Approved [1]
Therapeutic Class
Anticholesteremic Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=446155"></iframe>
3D MOL 2D MOL
Formula
C24H26FNO4
Canonical SMILES
CC(C)N1C2=CC=CC=C2C(=C1C=CC(CC(CC(=O)O)O)O)C3=CC=C(C=C3)F
InChI
InChI=1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m1/s1
InChIKey
FJLGEFLZQAZZCD-MCBHFWOFSA-N
CAS Number
CAS 93957-54-1
Pharmaceutical Properties Molecular Weight 411.473 Topological Polar Surface Area 82.7
Heavy Atom Count 30 Rotatable Bond Count 8
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 5
PubChem CID
446155
PubChem SID
100024002 , 10299838 , 103043439 , 103293858 , 104170157 , 104635874 , 10584685 , 10852031 , 117368355 , 121362529 , 126667384 , 130408282 , 131378297 , 135650279 , 136352753 , 136910868 , 137201916 , 143038598 , 144075757 , 144213082 , 14981407 , 152164360 , 152245639 , 162221786 , 163620805 , 163686130 , 165235894 , 172080782 , 175269733 , 175611054 , 176253518 , 176484235 , 24775765 , 36888653 , 46505668 , 47291222 , 48413791 , 48416032 , 49835750 , 49857384 , 50758963 , 53787111 , 56312811 , 56313633 , 57404724 , 7979295 , 822161 , 85856290 , 91613309 , 92308982
ChEBI ID
ChEBI:5136
TTD Drug ID
D08GHB
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
OATP1B1 Transporter Info Organic anion transporting polypeptide 1B1 Substrate [3]
OATP1B3 Transporter Info Organic anion transporting polypeptide 1B3 Substrate [4]
OATP2B1 Transporter Info Organic anion transporting polypeptide 2B1 Substrate [4]
P-GP Transporter Info P-glycoprotein 1 Substrate [5]
Drug-Transporter Activity Data
Drug-Transporter Activity Data OATP1B1 Transporter Info Km = 1.4 microM Chinese hamster ovary (CHO) cells-OATP1B1 [4]
OATP1B1 Transporter Info Km = 3.5 microM Chinese hamster ovary (CHO) cells-OATP1B1 [4]
OATP1B1 Transporter Info Km = 31.1 microM Oocytes-OATP1B1 [6]
OATP1B3 Transporter Info Km = 7 microM Madin-Darby canine kidney cells (MDCKII)-OATP1B3 [7]
OATP2B1 Transporter Info Km = 0.75 microM Human embryonic kidney cells (HEK293)-OATP2B1 [4]
References
1 Fluvastatin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates. Pharm Res. 2015 May;32(5):1634-47.
3 SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther. 2006 Oct;80(4):356-66.
4 Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007 Aug;35(8):1308-14.
5 A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
6 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
7 Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol. 2005 Oct;68(4):1031-8.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.